News Years after Pfizer merger, ex-Medivation exec gets insider t... A Medivation executive at the heart of the company's team that sold the company to Pfizer for $14 billion five years ago is facing allegations of insider trading.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face